EIKONOKLASTES THERAPEUTICS, INC.

CINCINNATI, OH · Founded 2019 · Biotech · Private

Small molecule therapeutics for challenging diseases using proprietary drug discovery platform

Claim this profile

Follows are private to you and power your alerts

Updated · eikonoklastes.com

Sector
Biotech
Headquarters
CINCINNATI, OH
Founded
2019
Latest Form D
$13.6M, Jul 2025
Total capital
$25M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$25M
6 Form D · last Jul 2025
15 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

202020212022202320242025FEDERAL ↑EQUITY ↓Cumulative $25M2nd Form D$3.2M3rd Form D$2.8M4th Form D$2M6th Form D$13.6M
202020212022202320242025FEDERAL ↑EQUITY ↓Cumulative $25M3rd Form D$2.8M

Latest events

  • Private capital raisedForm D · SEC · 6th filing$13.6M
  • Private capital raisedForm D · SEC · 5th filing$2.4M
  • Private capital raisedForm D · SEC · 4th filing$2M
  • Private capital raisedForm D · SEC · 3rd filing$2.8M
  • Private capital raisedForm D · SEC · 2nd filing$3.2M
  • Private capital raisedForm D · SEC · 1st filing$1.1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Bruce HalprynExecutive Officer, DirectorNamed in SEC Form D filings
  • Joseph NolanDirectorNamed in SEC Form D filings
  • Kenneth MorandDirectorNamed in SEC Form D filings
  • Meyer FrucherDirectorNamed in SEC Form D filings
  • Neel PatelDirectorNamed in SEC Form D filings
  • Robert JohnsonDirectorNamed in SEC Form D filings
Show all 8 people
  • Samuel LeeExecutive Officer, DirectorNamed in SEC Form D filings
  • Thomas FinnDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • BRICKBIO INC.Similar federal contract value in Biotech · null in contracts
  • EMERAMED LtdSimilar federal contract value in Biotech · null in contracts
  • Avana Health, Inc.Similar federal contract value in Biotech · null in contracts
  • Enlaza TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • PAINREFORM LTD.Similar federal contract value in Biotech · null in contracts
  • Isterian Biotech, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .